Dataset Information

No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis.

ABSTRACT:

Aim

Tissue inhibitor of metalloproteinase (TIMP2) is involved in the regulation of matrix metalloproteinase 2 (MMP2) and shown to implicate in cancer development and progression. The results from the published studies based on the association between TIMP2 -418 G>C polymorphism and cancer risk are inconsistent. In this meta-analysis, we aimed to evaluate the potential association between TIMP2 -418 G>C polymorphism and cancer risk.

Methodology

We searched PubMed (Medline) and EMBASE web databases to cover all studies based on relationship of TIMP2 -418 G>C polymorphism and risk of cancer until October 2013. The meta-analysis was performed for selected case-control studies and pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for all genetic models.

Results

A total of 2225 cancer cases and 2532 controls were included from ten eligible case-control studies. Results from overall pooled analysis suggested no evidence of significant risk between TIMP2 -418 G>C polymorphism and cancer risk in any of the genetic models, such as, allele (C vs. G: OR?=?1.293, 95% CI?=?0.882 to 1.894, p?=?0.188), homozygous (CC vs. GG: OR?=?0.940, 95% CI?=?0.434 to 2.039, p?=?0.876), heterozygous (GC vs. GG: OR?=?1.397, 95% CI?=?0.888 to 2.198, p?=?0.148), dominant (CC+GC vs. GG: OR?=?1.387, 95% CI?=?0.880 to 2.187, p?=?0.159) and recessive (CC vs. GG+GC: OR?=?0.901, 95% CI?=?0.442 to 1.838, p?=?0.774) models. No evidence of publication bias was detected during the analysis.

Conclusions

The present meta-analysis suggests that the TIMP2 -418 G>C polymorphism may not be involved in predisposing risk factor for cancer in overall population. However, future larger studies with group of populations are needed to analyze the possible correlation.

SUBMITTER: Mandal RK

PROVIDER: S-EPMC4138026 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis.

Mandal Raju K RK Akhter Naseem N Haque Shafiul S Panda Aditya K AK Mittal Rama D RD Alqumber Mohammed A A MA

PloS one 20140819 8

<h4>Aim</h4>Tissue inhibitor of metalloproteinase (TIMP2) is involved in the regulation of matrix metalloproteinase 2 (MMP2) and shown to implicate in cancer development and progression. The results from the published studies based on the association between TIMP2 -418 G>C polymorphism and cancer risk are inconsistent. In this meta-analysis, we aimed to evaluate the potential association between TIMP2 -418 G>C polymorphism and cancer risk.<h4>Methodology</h4>We searched PubMed (Medline) and EMBA ...[more]

PMID: 25136829

Similar Datasets

Project description:Background and objectiveThe gene betaine-homocysteine methyltransferase (BHMT) has drawn much attention during the past decades. An increasing number of clinical and genetic investigations have supposed that BHMT rs3733890 polymorphism might be associated with risk of breast cancer and ovarian cancer. As no consistent conclusion has been achieved, we conducted an up-to-date summary of BHMT rs3733890 polymorphism and cancer risk through a meta-analysis.Materials and methodsThe articles were collected from PubMed, Google Scholar, and CNKI (Chinese) databases up to December 2015. Then, the correlations were determined by reading the titles and abstracts and by further reading the full text to filter the unqualified articles. Odds ratio (OR) and the corresponding 95% confidence intervals (CI) were used to assess the results.ResultsAmong 187 articles collected in the analysis, seven studies with a total of 2,832 cases and 3,958 controls were included for evaluation of the association between BHMT rs3733890 polymorphism and susceptibility of cancer risk. The heterogeneity test showed no significant differences. Furthermore, we found that BHMT -742G>A polymorphism in case and control groups showed no statistically significant association with susceptibility in various cancer types except for uterine cervical cancer (A vs G: OR =0.641, 95% CI =0.445-0.923, P=0.017; AA+AG vs GG: OR =0.579, 95% CI =0.362-0.924, P=0.022). In addition, no statistically significant association was uncovered when stratification analyses were conducted by ethnicity and genotyping methods.ConclusionOur results have shown no obvious evidence that rs3733890 polymorphism in BHMT gene affected the susceptibility of head and neck squamous cell carcinoma, breast cancer, ovarian cancer, colorectal adenoma, and liver cancer. In contrast, we found the protective role of BHMT -742G>A polymorphism in uterine cervical cancer incidence. Future well-designed studies comprising larger sample size are warranted to verify our findings.

Project description:BackgroundNumerous studies have reported the correlation between AXIN2 polymorphism and cancer risk, but the results seem not consistent. In order to get an overall, accurate and updated results about AXIN2 polymorphism and cancer risk, we conducted this study.MethodsAn updated analysis was performed to analyze the correlation between AXIN2 polymorphisms and cancer risk. Linkage disequilibrium (LD) analysis was also used to show the associations.ResultsSeventy-two case-control studies were involved in the study, including 22,087 cases and 18,846 controls. The overall results showed rs11079571 had significant association with cancer risk (allele contrast model: OR = 0.539, 95%CI = 0.478-0.609, PAdjust = 0.025; homozygote model: OR = 0.22, 95% CI = 0.164-0.295, PAdjust< 0.001; heterozygote model: OR = 0.292, 95% CI = 0.216-0.394, PAdjust< 0.001; dominant model: OR = 0.249, 95% CI = 0.189-0.33, PAdjust< 0.001). The same results were obtained with rs1133683 in homozygote and recessive models (PAdjust< 0.05), and in rs35285779 in heterozygote and dominant models (PAdjust< 0.05). LD analysis revealed significant correlation between rs7210356 and rs9915936 in the populations of CEU, CHB&CHS, ESN and JPT (CEU: r2 = 0.91; CHB&CHS: r2 = 0.74; ESN: r2 = 0.62, JPT: r2 = 0.57), and a significant correlation between rs9915936 and rs7224837 in the populations of CHB&CHS, ESN and JPT (r2>0.5), between rs7224837 and rs7210356 in the populations of CEU, CHB&CHS, JPT (r2>0.5), between rs35435678 and rs35285779 in the populations of CEU, CHB&CHS and JPT (r2>0.5).ConclusionsAXIN2 rs11079571, rs1133683 and rs35285779 polymorphisms have significant correlations with overall cancer risk. What's more, two or more polymorphisms such as rs7210356 and rs9915936, rs9915936 and rs7224837, rs7224837 and rs7210356, rs35435678 and rs35285779 have significant correlation with cancer susceptibility in different populations.

Dataset Information

No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis.

Aim

Methodology

Results

Conclusions

Publications

No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets